Lakewood-Amedex to Execute 1-for-10 Reverse Stock Split Amid Listing Concerns
LABT is trading near its 52-week low of $0.59 (4.6% above the low) on light trading volume (0.2× avg).
Summary
Lakewood-Amedex Biotherapeutics announced a 1-for-10 reverse stock split of its common stock, effective June 19, 2026. This move is critical for the company, which is currently trading near its 52-week low at $0.61 and has a market cap of under $9 million. The reverse split is likely aimed at increasing the per-share price to meet NASDAQ's minimum bid requirement and avoid delisting. This follows the company's recent 10-Q filing which included a going concern warning and reported significant net losses, alongside a highly dilutive Series C financing.
At the time of this announcement, LABT was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.8M. The 52-week trading range was $0.59 to $9.82. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.